Immune Monitoring in 2026
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 December 2026 | Viewed by 1764
Special Issue Editors
Interests: memory B cell; vaccines; affinity maturation; IgG subclass usage
Special Issues, Collections and Topics in MDPI journals
2. Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA
Interests: HCMV; T cell; immune monitoring; peptide recognition
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immune reactivity in a test subject is generally advantageous when directed against viral, bacterial, or fungal pathogens or malignant cells. Alternatively, in the context of autoimmunity or allergy, immune reactivity that is inappropriate or misdirected can be detrimental to the host. Collectively, immune monitoring aims to measure whether an immune response has occurred within a test subject, and further to define its magnitude and quality.
In this Special Issue, we invite original research articles that examine antigen-specific T or B cell reactivity in test subjects in the context of vaccination, malignancy, autoimmunity, or allergy, especial those utilizing approaches and emerging techniques that provide single-cell resolution. Submissions related to the standardization and validation of immune monitoring methods that improve either the ease or throughput of sample testing are also highly encouraged.
Dr. Greg A. Kirchenbaum
Prof. Dr. Paul V. Lehmann
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- functional assay(s)
- antigen-specific (T/B) memory
- antibody reactivity
- Ig class/subclass usage
- Affinity maturation
- recall antigens
- peptide pools
- cytokine signature(s)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
